N6-methyladenosine-induced miR-182-5p promotes multiple myeloma tumorigenesis by regulating CAMK2N1

Bao, Jing; Xu, Tingting; Wang, Wanjie; Xu, Han; Chen, Xiaowen; Xia, Ruixiang

doi:10.1007/s11010-023-04906-w

Cited by 1 publication

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, it has been demonstrated that upregulation of METTL3 promotes the proliferation of MM cells. Furthermore, xenograft tumor in nude mice confirmed that METTL3 enhances MM tumor growth through the miR-182/CAMK2N1 signaling axis, suggesting a potential new target for MM therapy ( 67 ). Overall, the current researches on the impact of m6A modifications in MM predominantly focus on the reader protein, with limited exploration into the involvement of other factors in MM.…”

Section: Relevance Of M6a In the Pathogenesis Of Hematological Malign...mentioning

confidence: 98%

A new perspective on hematological malignancies: m6A modification in immune microenvironment

Yang,

Xu,

Zhuang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Immunotherapy for hematological malignancies is a rapidly advancing field that has gained momentum in recent years, primarily encompassing chimeric antigen receptor T-cell (CAR-T) therapies, immune checkpoint inhibitors, and other modalities. However, its clinical efficacy remains limited, and drug resistance poses a significant challenge. Therefore, novel immunotherapeutic targets and agents need to be identified. Recently, N6-methyladenosine (m6A), the most prevalent RNA epitope modification, has emerged as a pivotal factor in various malignancies. Reportedly, m6A mutations influence the immunological microenvironment of hematological malignancies, leading to immune evasion and compromising the anti-tumor immune response in hematological malignancies. In this review, we comprehensively summarize the roles of the currently identified m6A modifications in various hematological malignancies, with a particular focus on their impact on the immune microenvironment. Additionally, we provide an overview of the research progress made in developing m6A-targeted drugs for hematological tumor therapy, to offer novel clinical insights.

show abstract

Section: Relevance Of M6a In the Pathogenesis Of Hematological Malign...mentioning

confidence: 98%

A new perspective on hematological malignancies: m6A modification in immune microenvironment

Yang,

Xu,

Zhuang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

N6-methyladenosine-induced miR-182-5p promotes multiple myeloma tumorigenesis by regulating CAMK2N1

Cited by 1 publication

References 32 publications

A new perspective on hematological malignancies: m6A modification in immune microenvironment

A new perspective on hematological malignancies: m6A modification in immune microenvironment

Contact Info

Product

Resources

About